

HCG acquires 12% equity stake in ISSL

01 May 2018 | News

HealthCare Global, which has acquired 10,860 equity shares of ISSL for Rs 56 lakh in an all-cash deal, will help the company develop treatment for cancer.



Bengaluru-based oncology chain HealthCare Global Enterprises Ltd has acquired a 12 per cent equity stake in International Stemcell Services Ltd (ISSL) in a secondary deal that saw its existing shareholders divesting some of their holdings.

HealthCare Global, which has acquired 10,860 equity shares of ISSL for Rs 56 lakh in an all-cash deal, will help the company develop treatment for cancer.

Bengaluru-based ISSL is involved in stem cell research. It offers stem cell banking for regenerative medicine, including umbilical cord blood stem cells banking and mesenchymal stem cells banking from umbilical cord, stem cell therapies, and vaccine therapies for cancer patients. It also offers banking of bone marrow stem cells, peripheral blood mobilized stem cells, stem cells from lipo aspirate, and stem cell expansion and differentiation.

HealthCare Global operates 23 cancer care centres under the HCG brand and fertility centres under the Milann brand in India. It also operates multi-speciality hospitals in Ahmedabad, Bhavnagar, Rajkot, and Vadodara in Gujarat.